High-grade glioma in children under 5 years of age: A chemotherapy only approach with the BBSFOP protocol

Department of Pediatric and Adolescent, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif cedex, France. <>
European Journal of Cancer (Impact Factor: 5.42). 12/2006; 42(17):2939-45. DOI: 10.1016/j.ejca.2006.06.021
Source: PubMed


The aim of this study was to evaluate a chemotherapy strategy that avoids radiotherapy in first-line treatment of young children with high-grade glioma. A total of 21 children under 5 years of age received the BBSFOP protocol, comprising seven cycles of three drug pairs (carboplatin/procarbazine, cisplatin/etoposide and vincristine/cyclophosphamide) administered over a 16 month period. Radiotherapy was performed in case of recurrence/progression. Median age at diagnosis was 23 months. Histology was classified as World Health Organisation (WHO) grade III in 13 and grade IV in 8. Of the 13 children with a residual tumour, chemotherapy induced 2 partial responses (PR), 1 minor response (MR) and 1 stable disease (SD) with no recurrent disease. Five-year progression-free survival was 35% and 5-year overall survival was 59%, with a median follow-up of 5.2 years. At the last update, 12 children were alive (10 without radiotherapy). In conclusion, this study shows that an adjuvant chemotherapy first approach is safe and allows radiotherapy to be avoided in selected children.

Download full-text


Available from: Jean-Claude Gentet, Oct 05, 2015
27 Reads
  • Source
    • "Radiation therapy has become the mainstay of therapy, particularly for those children older than 3 y/o with newly diagnosed HGG. Since younger children are more susceptible to the negative deleterious effects associated with radiation therapy and they seem to harbor more indolent tumors, they are often treated with chemotherapy alone and radiationsparing approaches (Geyer et al., 1995; Duffner et al., 1996; Dufour et al., 2006; Sanders et al., 2007). For older children, focal radiotherapy with a margin around the tumor bed has become the standard. "
    [Show abstract] [Hide abstract]
    ABSTRACT: High grade gliomas (HGG) are one of the most common central nervous system (CNS) tumors encountered in adults, but they only represent approximately 8-12% of all pediatric CNS tumors. Historically, pediatric HGG were thought to be similar to adult HGG since they appear histologically identical; however, molecular, genetic, and biologic data reveal that they are distinct. Similar to adults, pediatric HGG are very aggressive and malignant lesions with few patients achieving long-term survival despite a variety of therapies. Initial treatment strategies typically consist of a gross total resection (GTR) when feasible followed by focal radiotherapy combined with chemotherapy. Over the last few decades, a wealth of data has emerged from basic science and pre-clinical animal models helping to better define the common biologic, genetic, and molecular make-up of these tumors. These data have not only provided a better understanding of tumor biology, but they have also provided new areas of research targeting molecular and genetic pathways with the potential for novel treatment strategies and improved patient outcomes. Here we provide a review of pediatric non-brainstem HGG, including epidemiology, presentation, histology, imaging characteristics, treatments, survival outcomes, and an overview of both basic and translational research. An understanding of all relevant pre-clinical tumor models, including their strengths and pitfalls is essential in realizing improved patient outcomes in this population.
    Frontiers in Oncology 08/2012; 2:105. DOI:10.3389/fonc.2012.00105
  • Source
    • "Among survivors, the mean follow up was 5.8 years (1.6-10.7). All patients were treated according to the gold standard protocols prevailing at the time of diagnosis, including the BB SFOP protocol (carboplatin, procarbazin, etoposide, cisplatin, vincristin and cyclophosphamide) (Dufour et al., 2006), the HIT-GBM 89 (CCNU, vincristin and prednisolone), the 8-in-1 regimen (vincristine, CCNU, procarbazine, hydroxyurea, cisplatin, cytarabine, dacarbine, and methylprednisolone) (Finlay et al., 1995) and Temozolomide alone. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Gliomas are the most common CNS tumours in children and present either as circumscribed tumours or diffusely infiltrative neoplasms. Diffuse gliomas develop both in the cerebral hemispheres and the brainstem and have a poor prognosis. Guidelines for the therapy of these tumours are still debated. In this study, we reviewed the clinical features of 27 consecutive patients with diffuse gliomas admitted to the Department of Paediatrics of CHR Citadelle, University of Liège, between 1985 and 2005. We review their clinical presentation, diagnosis, treatment and outcome with reference to the published literature.
    Acta neurologica Belgica 07/2008; 108(2):35-43. · 0.89 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Tumors of the central nervous system (CNS) are the leading cause of cancer-related mortality in children. Brain tumors account for approximately 25% of pediatric cancers. They rank second behind leukemia as the most common pediatric cancer diagnosed in the United States each year, and they are the most common form of solid tumor in children. Improvement in outcome for pediatric brain tumors has lagged far behind that of many other cancers, especially childhood leukemia. The complexity of curing pediatric brain tumors is related to the large number of different histologies within the CNS and the need to modify therapies to spare neurocognitive function in young patients.
    Cancer chemotherapy and biological response modifiers 02/1987; 9:390-401.
Show more